Cyberknife Dosimetric Planning Using a Dose-Limiting Shell Method for Brain Metastases

Kyoung Jun Yoon, Ph.D.,1 Byungchul Cho, Ph.D.,2 Jung Won Kwak, Ph.D.,2 Doheui Lee, Ph.D.,1 Do Hoon Kwon, M.D., Ph.D.,3 Seung Do Ahn, M.D., Ph.D.,2 Sang-Wook Lee, M.D., Ph.D.,2 Chang Jin Kim, M.D., Ph.D.,2 Sung Woo Roh, M.D., Ph.D.,3 Young Hyun Cho, M.D., Ph.D.2

Radiotherapy Center,1 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Department of Radiation Oncology,2 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Department of Neurosurgery,3 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Objective: We investigated the effect of optimization in dose-limiting shell method on the dosimetric quality of CyberKnife (CK) plans in treating brain metastases (BMs).

Methods: We selected 19 BMs previously treated using CK between 2014 and 2015. The original CK plans (CK_original) had been produced using 1 to 3 dose-limiting shells: one at the prescription isodose level (PIDL) for dose conformity and the others at low-isodose levels (10–30% of prescription dose) for dose spillage. In each case, a modified CK plan (CK_modified) was generated using 5 dose-limiting shells: one at the PIDL, another at intermediate isodose level (50% of prescription dose) for steeper dose fall-off, and the others at low-isodose levels, with an optimized shell-dilation size based on our experience. A Gamma Knife (GK) plan was also produced using the original contour set. Thus, three data sets of dosimetric parameters were generated and compared.

Results: There were no differences in the conformity indices among the CK_original, CK_modified, and GK plans (mean 1.22, 1.18, and 1.24, respectively; \( p = 0.079 \)) and tumor coverage (mean 99.5%, 99.5%, and 99.4%, respectively; \( p = 0.177 \)), whereas the CK_modified plans produced significantly smaller normal tissue volumes receiving 50% of prescription dose than those produced by the CK_original plans (\( p < 0.001 \)), with no statistical differences in those volumes compared with GK plans (\( p = 0.345 \)).

Conclusion: These results indicate that significantly steeper dose fall-off is able to be achieved in the CK system by optimizing the shell function while maintaining high conformity of dose to tumor.

Key Words: Radiosurgery · Brain · Neoplasm metastasis.
than a certain threshold dose has been implicated in the development of radiation necrosis (RN)\(^1,2,11,14\). A quality SRS plan requires a dose fall-off as steep as possible outside the target and an optimal dose conformity to the target\(^15,21,22\).

To evaluate the dose fall-off property of SRS, the dose gradient index (GI), which is the ratio of the isodose volume receiving 50% of the prescription dose (PD) to the prescription isodose volume (PIV), has been proposed and used\(^3,6,9,13,19,20,23,24\). Studies that compared GIs among SRS modalities demonstrated the Gamma Knife (GK; Elekta, Stockholm, Sweden) to be superior to other modalities such as the CyberKnife (CK; Accuray, Sunnyvale, CA, USA) and Novalis Tx (Varian Medical Systems, Palo Alto, CA, USA)\(^6,9,20,24\); these findings might be translated into clinical relevance regarding radiation toxicity.

To minimize the risks of radiation-induced toxicities such as RN, the concept of hypofractionated SRS has emerged and is reportedly effective and safe, particularly for treating large BMs\(^4,5,7,8,10,12,17,18\). Since 2011, we adopted this approach using the CK system for large lesions with diameters of >2.5 cm. In addition to a flexible fractionation delivery of SRS, CK allows an inverse planning system along with a number of beams up to 1500 either isocentric or non-isocentric that can be adjusted depending on the clinical situation. Among factors involved in the sequential optimization process in CK planning, a dose-limiting shell function is used to create virtual shell structures around or outside the target, which limit a certain threshold dose. In pursuit of high precision in target localization (dose conformity and tumor coverage) together with steep dose fall-off outside the target, we investigated the impact of optimization in dose-limiting shell function on the dosimetric quality of CK plans in treating BMs.

**MATERIALS AND METHODS**

The Institutional Review Board approved this retrospective study (IRB No. 2014-0574) and informed consent was waived because of the retrospective nature of the study. For this study, we selected 19 BMs from 19 patients (median age, 58 years; 12 women and seven men) who had been treated with SRS using CK (version 9.5; Accuray) at our institution between October 2014 and May 2015. Primary cancers originated from the lung (n=7), gastrointestinal tract (n=5), and breast (n=7). Tumor volume ranged from 2.1 cm\(^3\) to 48.0 cm\(^3\) (median, 11.1 cm\(^3\)).

To achieve steeper dose fall-off in normal brain tissue outside the target, we recently modified our previous CK planning technique to introduce a more systematic application of dose-limiting shells. In this modified technique, shells were applied at prescription isodose level (PIDL) for dose conformity; at intermediate isodose level (50% of PD) for rapid dose fall-off, and at low-isodose levels (10–30% of PD) for dose spillage. Accordingly, a modified CK plan (CK\(_{\text{modified}}\)) was produced in each case and compared with the original CK plan (CK\(_{\text{original}}\)). In addition, a GK plan was also produced using the original contour set (DICOM RadioTherapy Structure Set) of each lesion transferred to the Elekta GammaPlan system (version 9.0; Elekta, Stockholm, Sweden). Thus, triplet data sets of dosimetric parameters for each lesion were generated and analyzed.

**Original CK plans**

All patients were immobilized by using a thermoplastic mesh mask. The planning computed tomography (CT) images (1.25-mm slice thickness) were fused with gadolinium-enhanced three-dimensional T1 magnetization-prepared rapid acquisition gradient echo magnetic resonance images (MRI; 1.5-mm slice) in the Accuray MultiPlan system (version 4.5; Accuray) to facilitate delineation of the gross tumor volume (GTV; equal to planning target volume) and critical organ structures, including the brainstem, eyes, and optic apparatus. The sequential optimization method was used to produce all CK plans with the planning objectives of GTV coverage (CO) >99%, conformity index (CI) <1.2, and treatment time <60 minutes. A median 31 Gy (range, 22–35) was prescribed at the tumor margin of a median 75% isodose level (range, 70–81%) normalized to the maximum dose in a single session (n=5; small tumors <2.5 cm) or five daily fraction treatment (n=14; large tumors >2.5 cm). One to three fixed collimators were selected to achieve a size 30–70% of the tumor diameter depending on the tumor size and shape. One to three dose-limiting shells were used at PIDL and at low-isodose levels. A ray-tracing algorithm was used for dose calculation.

**Modified CK plans and GK plans**

In each case, a CK\(_{\text{modified}}\) and a GK plan were produced by using the identical planning CT/MRI and contour set of the lesion. In the CK\(_{\text{modified}}\) plan, five dose-limiting shells were
used: one at PIDL, another at intermediate isodose level (50% of PD), and the other three at low-isodose levels (each at 30%, 20%, and 10% of PD). An adequate shell size at each isodose level was estimated on the basis of our previous study on favorable dose fall-off profiles of GK relative to those of CK\(^3\). As shown in Fig. 1, the radial distance of a shell from the margin of the target at each isodose level was calculated according to the following equation.

\[ \text{Distance of shell}_i = \text{RGTV} \times M_i - \text{RGTV} \]

Where \( \text{RGTV} \) is the equivalent spherical radius of GTV, and \( \text{RGTV} \times M_i \) is another equivalent spherical radius for an expanded volume of GTV (shell) achieved by applying an empirically determined multiplication factor of \( M_i \).

**Table 1.** Dilation sizes of dose-limiting shells are listed according to the gross tumor volume

| Gross tumor volume (mL) | Prescription isodose level | Intermediate isodose level | Low-isodose levels |
|-------------------------|-----------------------------|----------------------------|-------------------|
|                         | Shell1* (mm) | M1 | Shell2* (mm) | M2 | Shell3* (mm) | M3 | Shell4* (mm) | M4 | Shell5* (mm) | M5 |
| <2                      | 2.0          | 2.0 | 3.5          | 3.0 | 10.6          | 13.0 | 20.0          | 45.0 | 28.5          | 100.0 |
| <3                      | 2.1          | 1.9 | 4.0          | 3.0 | 12.1          | 13.0 | 21.7          | 40.0 | 30.4          | 85.0  |
| <4                      | 2.1          | 1.8 | 4.4          | 3.0 | 13.3          | 13.0 | 22.7          | 36.0 | 31.7          | 75.0  |
| <5                      | 2.1          | 1.7 | 4.7          | 3.0 | 13.7          | 12.0 | 23.4          | 33.0 | 32.0          | 65.0  |
| <10                     | 2.3          | 1.6 | 5.9          | 3.0 | 16.4          | 11.0 | 25.7          | 25.0 | 34.2          | 45.0  |
| <15                     | 2.2          | 1.5 | 6.8          | 3.0 | 17.7          | 10.0 | 26.9          | 21.0 | 37.0          | 40.0  |
| <20                     | 2.0          | 1.4 | 7.4          | 3.0 | 18.2          | 9.0  | 27.3          | 18.0 | 37.7          | 34.0  |
| <30                     | 2.0          | 1.4 | 8.5          | 3.0 | 19.3          | 8.0  | 30.3          | 17.0 | 40.6          | 30.0  |
| <50                     | 2.1          | 1.3 | 10.1         | 3.0 | 22.9          | 8.0  | 34.7          | 16.0 | 48.2          | 30.0  |

\( \text{RGTV} \) is the equivalent spherical radius of the gross tumor volume (\( \text{RGTV} = \left( \frac{3 \times \text{GTV}}{4 \pi} \right) \)). \( \text{RGTV} \times M_i \) is another equivalent spherical radius for an expanded volume of the GTV (shell) by a multiplication factor of \( M_i \) that is empirically determined as \( M_i = 1.3 \) to 2.0, \( M_i = 3 \), \( M_i = 8 \) to 13, \( M_i = 16 \) to 45, and \( M_i = 30 \) to 100. *Shell = \( \text{RGTV} \times M_i - \text{RGTV} \)

**Fig. 1.** A schematic representation of the relationship between the gross tumor volume (GTV) and dose-limiting shells. \( \text{RGTV} \) is the equivalent spherical radius of the GTV, and \( \text{RGTV} \times M_i \) is another equivalent spherical radius for an expanded volume of the GTV (shell) achieved by applying an empirically determined multiplication factor of \( M_i \).

**Comparison of dosimetric parameters and statistical analysis**

In the triplet plans produced, the minimum, mean, and maximum doses in the target volume, CI, CO, homogeneity index (HI), GI50, GI25, V12BED, and V10BED were calculated and compared. CI was defined as the ratio of the PIV to the volume of tumor receiving the PD or more. HI was defined as the ratio of the maximum dose to the PD. GI was defined as the ratio of the maximum dose to the PD. GI50 and GI25 were
the ratios of the isodose volumes receiving 50% and 25% of PD, respectively, to PIV\(^{17}\). V\(_{12\,\text{BED}}\) and V\(_{10\,\text{BED}}\) were the tissue volumes receiving the biologically equivalent dose corresponding to 12 and 10 Gy or more in a single session (assuming an lumes 10), respectively.

For detailed analysis of peripheral dose fall-off outside PIV, tissue volumes at multiple isodose levels from 90% to 10% of the PD were obtained and normalized to the PIV (relative tissue volumes to PIV), and compared. Dosimetric data were analyzed using the paired t-test or the repeated measures analysis of variance (SPSS Statistics, version 22; IBM, Chicago, IL, USA). Significance levels were set as \(p \leq 0.05\) for the paired t-test and \(p \leq 0.05/3\) for the Bonferroni correction for multiple comparisons.

**RESULTS**

The treatment planning parameters and dosimetric indices for the CK\(_{\text{original}}\), CK\(_{\text{modified}}\), and GK plans are summarized in Table 2. Both CK plans used the same collimator (range, 1–3; median, 3) and prescription isodose level (range, 70–80%; mean, 74%). In the CK\(_{\text{original}}\) and CK\(_{\text{modified}}\) plans, the median numbers of shells used were 3 (range, 1–3) and 5 (range, 5–5), respectively (\(p<0.001\)). Since the number of beams (mean, 189 and 201; \(p=0.158\)) increased in CK\(_{\text{modified}}\) plans as the number of shells was added, the treatment time (mean, 52 and 54; \(p=0.304\)) slightly increased, though there was no statistical significance.

The mean and maximum doses to GTV and HI were significantly higher in GK plans than those in both CK plans, whereas the minimum dose was significantly lower in GK (each \(p<0.001\)). In terms of precision in target localization, all three plans represented a high degree of dose conformity (CI=1.2±0.1) and tumor coverage (CO>99%), with no significant differences in these values among the plans, as shown in Table 2, Fig. 2A and B.

Regarding the dose to surrounding normal tissue, CK\(_{\text{modified}}\) plans produced significantly lower values of GI50 and GI25 than those produced by CK\(_{\text{original}}\) plans (each \(p<0.001\)), with no statistical differences in those values compared with GK plans (\(p=0.345\) and \(p=0.087\), respectively). Consistent with these, V\(_{12\,\text{BED}}\) and V\(_{10\,\text{BED}}\) were significantly smaller in CK\(_{\text{modified}}\) plans than in CK\(_{\text{original}}\) plan (each \(p<0.001\)), and these values

| Table 2. Summary of the CyberKnife and Gamma Knife plan parameters (19 cases) |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | 1                               | 2                               | 3                               | Overall                         | 1 vs. 2 | 1 vs. 3 | 2 vs. 3 |
|                                 | CK\(_{\text{original}}\)        | CK\(_{\text{modified}}\)        | GK                              | p-value*                        | p-value | p-value | p-value |
| Prescription isodose level (%) | 73.89                           | 73.89                           | 50                              | NA                              | NA      | NA      | NA      |
| Number of beams                 | 189.6±43.5                      | 201.1±56.9                      | NA                              | NA                              | 0.158   | NA      | NA      |
| Treatment time/fraction (minutes) | 52.1±6.1                        | 54.2±6.5                        | 40.2±18                        | <0.001                          | 0.304   | <0.001  | <0.001  |
| D\(_{\text{min}}\) (Gy)         | 28.8±5.3                        | 28.0±5.5                        | 25.3±5.7                       | <0.001                          | <0.001  | <0.001  | <0.001  |
| D\(_{\text{mean}}\) (Gy)        | 35.1±6.0                        | 36.5±6.0                        | 43±4.7                         | <0.001                          | <0.001  | <0.001  | <0.001  |
| D\(_{\text{max}}\) (Gy)         | 41.1±6.7                        | 41.3±6.6                        | 60.9±11                        | <0.001                          | 0.310   | <0.001  | <0.001  |
| HI                              | 1.4±0.1                         | 1.4±0.1                         | 2.0±0.0                        | <0.001                          | 0.563   | <0.001  | <0.001  |
| CI                              | 1.2±0.1                         | 1.18±0.1                        | 1.24±0.1                       | 0.079                           | 0.064   | 0.407   | 0.061   |
| CO                              | 99.5±0.4                        | 99.5±0.3                        | 99.4±0.2                       | 0.177                           | 0.636   | 0.199   | 0.018   |
| GI50                            | 3.5±0.3                         | 2.7±1.2                         | 2.7±0.2                        | <0.001                          | <0.001  | <0.001  | 0.345   |
| GI25                            | 9.3±1.6                         | 7.7±1.2                         | 7.4±1.1                        | <0.001                          | <0.001  | <0.001  | 0.087   |
| V\(_{12\,\text{BED}}\) ^‡       | 49.1±40.0                       | 38.3±34.0                       | 39.8±33.9                      | <0.001                          | <0.001  | <0.001  | 0.030   |
| V\(_{10\,\text{BED}}\) ^‡       | 65.2±52.8                       | 51.7±47.1                       | 53.6±45.7                      | <0.001                          | <0.001  | <0.001  | 0.053   |

Values are presented as mean±standard deviation. *Statistical significance, \(p<0.05\). †Bonferroni-corrected statistical significance, \(p<0.0167\) (=0.05/3). ^‡V\(_{12\,\text{BED}}\) and V\(_{10\,\text{BED}}\) volumes receiving the biologically equivalent dose corresponding to 12 and 10 Gy or more in a single session (assuming an lumes 10), respectively. CK\(_{\text{original}}\) : original CyberKnife plan, CK\(_{\text{modified}}\) : modified CyberKnife plan, GK : Gamma Knife plan, NA : not applicable, D\(_{\text{min}}\) : the minimum dose, D\(_{\text{mean}}\) : mean dose, D\(_{\text{max}}\) : maximum dose, HI : homogeneity index, CI : conformity index, CO : tumor coverage, GI : gradient index

https://doi.org/10.3340/jkns.2018.0075
were even slightly smaller in CK\textsubscript{modified} plans than in GK plans, with significant or marginally significant differences ($p=0.030$ and $p=0.053$, respectively) (Table 2). Fig. 2C shows that these results are independent of tumor size. A representative case of optimized dose fall-off using the modified CK planning technique is illustrated in Fig. 3.

To evaluate the peripheral dose fall-off in more detail, relative tissue volumes to the PIV at multiple isodose levels from 90\% to 10\% of PD were calculated and analyzed using a linear mixed model (Table 3). At all isodose levels except at 10\%, the relative tissue volumes were significantly smaller in CK\textsubscript{modified} plans than in the CK\textsubscript{original}, while no statistical differences in these volumes were observed between CK\textsubscript{modified} plans and GK plans except at 90\% isodose level.

**DISCUSSION**

GK is the “gold standard” intracranial SRS modality, whereas CK is a relatively new one featuring a frameless and image-guided robotic system enabling a more flexible fractionation delivery of SRS as well as extracranial applications. Recently, a new model of Gamma Knife Icon\textsuperscript{TM}, which also provides frameless SRS solution using cone beam CT-based image guidance, has been available\textsuperscript{25}. As a comprehensive SRS center, our institution has been treating BMs by using either GK for single-session SRS or CK for hypofractionated SRS according to tumor size and location. The GK system, with its unique single- or multiple-isocentric dosimetric technique using 192 Cobalt-60 sources fixed and arranged around the target, is renowned for stably delivering a high-quality SRS of very steep dose

![Fig. 2. Comparison of dosimetric indices plotted against tumor diameters in all 19 cases. Each black circle, blue square, and red triangle represents the value in the CK\textsubscript{original}, CK\textsubscript{modified}, and GK plan, in terms of the conformity index (A), tumor coverage (B), and gradient index (C). CK\textsubscript{original} : original CyberKnife plan, CK\textsubscript{modified} : modified CyberKnife plan, GK : Gamma Knife plan.](image-url)
Fig. 3. A representative case of optimized dose fall-off when using the modified CK planning technique. In the original CK plan (A), a single shell (green line) with a distance of 3 mm from the margin of the tumor volume (shaded in red; 14.8 cm³ in this case) was used (top). The multiple isodose lines presented in the planned dosimetric image (bottom). The isodose lines represent the percentage of the prescription dose. In the modified CK plan (B), 5 shells with distances of 2, 7, 18, 28, and 38 mm from the tumor margin were introduced and used (top). Note that the isodose lines are arranged more compactly in the planned image (bottom) than in the original plan. The value of the gradient index 3.4 in the original plan decreased to 2.5 in the modified plan in this case. In the GK plan (C), the value of the gradient index was 2.6. GTV : gross tumor volume, CK : CyberKnife.

Table 3. Comparison of peripheral dose fall-off among the CyberKnife and Gamma Knife plans

| Volumes* at percent of the prescription dose | 1 | 2 | 3 | Overall | Multiple comparisons |
|-------------------------------------------|---|---|---|---------|----------------------|
|                                           | CK_original | CK_modified | GK | p-value† | 1 vs. 2 | 1 vs. 3 | 2 vs. 3 |
| 100                                      | 1           | 1           | 1  | NA      | NA  | NA  | NA  |
| 90                                       | 1.35±0.0    | 1.22±0.0    | 1.19±0.0 | <0.001 | <0.001 | <0.001 | 0.008 |
| 80                                       | 1.73±0.0    | 1.45±0.0    | 1.43±0.0 | <0.001 | <0.001 | <0.001 | 0.369 |
| 70                                       | 2.16±0.0    | 1.73±0.0    | 1.72±0.0 | <0.001 | <0.001 | <0.001 | 0.707 |
| 60                                       | 2.71±0.0    | 2.10±0.0    | 2.15±0.0 | <0.001 | <0.001 | <0.001 | 0.236 |
| 50                                       | 3.46±0.1    | 2.65±0.1    | 2.72±0.1 | <0.001 | <0.001 | <0.001 | 0.345 |
| 40                                       | 4.65±0.1    | 3.67±0.1    | 3.76±0.1 | <0.001 | <0.001 | <0.001 | 0.435 |
| 30                                       | 6.96±0.2    | 5.74±0.2    | 5.68±0.2 | <0.001 | <0.001 | <0.001 | 0.823 |
| 20                                       | 13.44±0.6   | 11.27±0.6   | 10.51±0.6 | 0.002  | 0.012  | <0.001 | 0.364 |
| 10                                       | 40.12±3.0   | 42.31±3.0   | 25.49±3.0 | <0.001 | 0.115  | <0.001 | <0.001 |

Values are presented as mean±standard error. *Relative tissue volumes to the prescription isodose volume at isodose levels from 90% to 10% of the prescription dose. †Linear mixed model. CK_original : original CyberKnife plan, CK_modified : modified CyberKnife plan, GK : Gamma Knife plan, NA : not applicable
fall-off as well as high precision in target localization. Studies comparing dosimetric quality among SRS modalities generally support the superiority of GK to other systems\(^3,6,9,13,20,24\), although competing data are also available\(^13,23\). In treating BMs, especially in large tumors >2.5 cm, dosimetric steepness outside the target and geometric accuracy for target localization should be optimized to minimize the potential risks of RN. In this regard, we introduced a systematic application of the shell function provided by the CK system and improved our CK plan quality, which has been shown to be comparable at least to GK.

Five shells with their specific purpose were introduced outside the target: the first one at PIDL to optimize dose conformity, the second at 50% of PD to steepen dose fall-off in normal tissue, and the remaining three to control dose spillage in low-isodose area. The distance of shells from the tumor margin was inversely calculated from the preferable output values of CI and GIs at isodose lines 50%, 30%, 20%, and 10% of PD, in reference to our previous GK and CK dosimetric data in BMs\(^3\).

In accordance with our planning objectives of CO >99% and CI <1.2, all of our original and modified CK and GK plans were able to produce comparably high conformity of dose to tumor. Several previous studies\(^3,6,9,13,20,24\) have reported consistent results with ours, although others reported inconsistent data\(^20,23\). We actually believe that high precision in target localization depends on the physician’s policy and the planning physicist’s expertise rather than on the SRS machines. On the other hand, in terms of dose fall-off properties, our previous CK plans produced significantly inferior results to GK at all isodose levels. This finding may be explained, in part, by the use of numerous non-isocentric beams to construct SRS by the CK system. However, our results from the modified CK planning technique, showed a sufficient compensation for dose fall-off by optimization of the shell function. As shown in Table 2 and Fig. 2, CK\(^{\text{modified}}\) plans achieved comparable values of GI50 and GI25 to GK plans while maintaining high conformity and dose coverage to tumor. Furthermore, V12\(_{\text{BED}}\) and V10\(_{\text{BED}}\) which were reported to be significantly associated with the development of RN\(^1,2,16\), have been shown to be slightly smaller in CK\(^{\text{modified}}\) plans than in GK plans. We speculate that an “isocentricity,” that is, the degree of the use of cross-firing isocentric beams of CK plans, may have been increased by introducing multiple dose-limiting shells outside the target, thereby resulting in steeper dose fall-off in normal brain tissue. Based on these results, our technique may enhance the safety of SRS in treating BMs, especially in large tumors, which needs to be further validated.

One potential trade-off of our modified CK planning technique is an increased number of beams used with strict application of dose-limiting shells outside the target, possibly resulting in an increased treatment time. Actually, the average percent increases in the number of beams and treatment time were 5.9% and 4.1%, respectively in our CK\(^{\text{modified}}\) plans, but the differences were not statistically significant, and treatment times <60 minutes are considered clinically feasible. In addition, the increased number of beams seems to affect dose control for low-isodose area less than 10% of PD (Table 3), but there was no statistical difference.

**CONCLUSION**

Our current study indicates that significantly steeper dose fall-off is able to be achieved using the CK system by optimization of the dose-limiting shell function while maintaining high conformity and dose coverage to tumor. The quality of CK plans produced in this way appears to be comparable at least to that of GK in terms of these parameters.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**INFORMED CONSENT**

Informed consent was obtained from all individual participants included in this study.

**Acknowledgements**

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2015M2A2A6A02045253 and 2016R1C1B2014792) and by the Radiation Technology R&D
1. Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC: Inactivated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77: 996-1001, 2010
2. Chin LS, Ma L, DiBiase S: Radiation necrosis following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow up. J Neurosurg 94: 899-904, 2001
3. Cho YH, Lee JM, Lee D, Park JH, Yoon K, Kim SO, et al.: Experiences on two different stereotactic radiosurgery modalities of Gamma Knife and Cyberknife in treating brain metastases. Acta neurochir (Wien) 157: 2003-2009, discussion 2009, 2015
4. Fahrig A, Ganslandt O, Lambrecht U, Grabenbauer G, Kleinert G, Sauer R, et al.: Hypofractionated stereotactic radiotherapy for brain metastases-results from three different dose concepts. Strahlenther Onkol 183: 629-630, 2007
5. Feuvret L, Vinchon S, Martin V, Lamproglou I, Halley A, Calugaru V, et al.: Stereotactic radiotherapy for large solitary brain metastases. Cancer Radiother 18: 97-106, 2014
6. Gevaert T, Levivier M, Lacornerie T, Verellen D, Engels B, Reynaert N, et al.: Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of arteriovenous malformations and acoustic neuromas. Radiother Oncol 106: 192-197, 2013
7. Giubilei C, Ingrosso G, D’Andrea M, Benassi M, Santoni R: Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases. J Neurooncol 91: 207-212, 2009
8. Jiang XS, Xiao JP, Zhang Y, Xu YJ, Li XP, Chen XJ, et al.: Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters. Radiat Oncol 7: 36, 2012
9. Kaul D, Badakhshi H, Gevaert T, Pasemann D, Budach V, Tulesasca C, et al.: Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of meningioma. Acta Neurochir (Wien) 157: 559-563; discussion 563-564, 2015
10. Kim YJ, Cho KH, Kim JY, Lim YK, Min HS, Lee SH, et al.: Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 81: 483-489, 2011
11. Korytko T, Radijojevitch T, Colussi V, Wessels BW, Pillai K, Macinias RJ, et al.: 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys 64: 419-424, 2006
12. Kwon AK, Dibiase SJ, Wang B, Hughes SL, Milcarek B, Zhu Y: Hypofractionated stereotactic radiotherapy for the treatment of brain metastases. Cancer 115: 890-898, 2009
13. Ma L, Sahgal A, Descovich M, Cho YB, Chuang C, Huang K, et al.: Equivalence in dose fall-off for isocentric and nonisocentric intracranial treatment modalities and its impact on dose fractionation schemes. Int J Radiat Oncol Biol Phys 76: 943-948, 2010
14. Massager N, Maris C, Kissim O, Devriendt D, Salmon I, Levivier M: Experimental analysis of radiation dose distribution in radiosurgery. II. Dose fall-off outside the target volume. Stereotact Funct Neurosurg 87: 137-142, 2009
15. Meeks SL, Buatti JM, Bova FJ, Friedman WA, Mendenhall WM: Treatment planning optimization for linear accelerator radiosurgery. Int J Radiat Oncol Biol Phys 41: 183-197, 1998
16. Minniti G, Clarke E, Lanzetta G, Osi MF, Trasimeni G, Bova FJ, et al.: Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6: 48, 2011
17. Minniti G, D’Angelillo RM, Scarinci C, Trodella LE, Clarke E, Matteucci P, et al.: Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol 117: 295-301, 2014
18. Murai T, Oghino H, Manabe Y, Iwabuchi M, Okumura T, Matsushita Y, et al.: Fractionated stereotactic radiotherapy using CyberKnife for the treatment of large brain metastases: a dose escalation study. Clin Oncol (R Coll Radiol) 26: 151-158, 2014
19. Paddick I, Lippitz B: A simple dose gradient measurement tool to complement the conformity index. J Neurosurg 105 Suppl: 194-201, 2006
20. Sio TT, Jang S, Lee SW, Curran B, Pyakuryal AP, Sternick ES: Comparing Gamma Knife and CyberKnife in patients with brain metastases. J Appl Clin Med Phys 15: 4095, 2014
21. Solberg TD, Balter JM, Benedict SH, Fraass BA, Kavanagh B, Miyamoto C, et al.: Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: executive summary. Pract Radiat Oncol 2: 2-9, 2012
22. Wagner TH, Bova FJ, Friedman WA, Buatti JM, Bouchet LG, Meeks SL: A simple and reliable index for scoring rival stereotactic radiosurgery plans. Int J Radiat Oncol Biol Phys 57: 1141-1149, 2003
23. Worrall B, Muacevic A, Tonni JC: Quality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysis. J Neurooncol 94: 69-77, 2009
24. Yu C, Cozof G, Apuzzo ML, Petrovich Z: Dosimetric comparison of CyberKnife with other radiosurgical modalities for an ellipsoidal target. Neurosurgery 53: 1155-1162; discussion 1162-1163, 2003
25. Zeverino M, Jaccard M, Patin D, Ryckx N, Marquet M, Tulesasca C, et al.: Commissioning of the leksell Gamma Knife® Icon™. Med Phys 44: 355-363, 2017